MAKO Surgical (NAS: MAKO) is expected to report Q3 earnings on Nov. 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MAKO Surgical's revenues will increase 37.3% and EPS will remain in the red.
The average estimate for revenue is $27.5 million. On the bottom line, the average EPS estimate is -$0.16.
Last quarter, MAKO Surgical logged revenue of $23.7 million. GAAP reported sales were 27% higher than the prior-year quarter's $18.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.20. GAAP EPS were -$0.20 for Q2 versus -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 73.1%, 260 basis points better than the prior-year quarter. Operating margin was -35.9%, 1,810 basis points better than the prior-year quarter. Net margin was -36.1%, 1,720 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $107.0 million. The average EPS estimate is -$0.74.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,165 members out of 1,209 rating the stock outperform, and 44 members rating it underperform. Among 250 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 239 give MAKO Surgical a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $34.57.
Add MAKO Surgical to My Watchlist.
The article Will MAKO Surgical Beat These Analyst Estimates? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of MAKO Surgical. Motley Fool newsletter services recommend MAKO Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.